NASDAQ:CYCCP
Cyclacel Pharmaceuticals Inc Stock News
$8.40
+0.91 (+12.15%)
At Close: May 31, 2024
Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results
09:15am, Thursday, 03'rd Nov 2022
BERKELEY HEIGHTS, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m
- Preliminary Dose Escalation Data to be Presented on Novel CDK2/9 Inhibitor Fadraciclib in Patients with Solid Tumors and Lymphoma - - Preliminary Dose Escalation Data to be Presented on Novel CDK2/9
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference
09:15am, Wednesday, 21'st Sep 2022
BERKELEY HEIGHTS, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2022 Results - Earnings Call Transcript
08:16pm, Wednesday, 10'th Aug 2022
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Irina Koffler - LifeSci Advisors Spiro Rombotis - President and Chief Exe
Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results
09:15am, Wednesday, 03'rd Aug 2022
BERKELEY HEIGHTS, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2022 Results - Earnings Call Transcript
08:45pm, Wednesday, 11'th May 2022
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Irina Koffler - LifeSci Advisors Spiro Rombotis - President, CEO & Executive
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2021 Results - Earnings Call Transcript
08:13pm, Monday, 28'th Mar 2022
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2021 Results - Earnings Call Transcript
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q3 2021 Results - Earnings Call Transcript
08:49pm, Wednesday, 10'th Nov 2021
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q3 2021 Results - Earnings Call Transcript
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2021 Results - Earnings Call Transcript
08:30pm, Wednesday, 11'th Aug 2021
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2021 Results - Earnings Call Transcript
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2021 Results - Earnings Call Transcript
09:02pm, Wednesday, 12'th May 2021
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2021 Results - Earnings Call Transcript
Cyclacel to Present at the Oppenheimer 31st Annual Healthcare Conference
07:16am, Monday, 15'th Mar 2021
BERKELEY HEIGHTS, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative
Cyclacel Pharmaceuticals Presses Capital Raise Button
11:50am, Friday, 12'th Mar 2021
Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) priced an underwritten public offering of 1.81 million common shares at $7 per share, a discount of 11% on the last close price of $7.87 on Thursday. It
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2020 Results - Earnings Call Transcript
10:40pm, Thursday, 25'th Feb 2021
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2020 Results - Earnings Call Transcript
Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021
07:46am, Monday, 11'th Jan 2021
– Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors – – Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer – – $7 Million Strategic Inve
Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021
07:00am, Wednesday, 30'th Dec 2020
BERKELEY HEIGHTS, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m
